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ABSTRACT 
Objective 
Hypoglycemia exerts proarrhythmogenic effect on the heart via sympathoadrenal stimulation 
and hypokalemia. Hypoglycemia-induced cardiac dysrhythmias DUH OLQNHG WR WKH µDead in 
EHG¶ V\QGURPH, a rare, but devastating event. We examined the effect of nocturnal and 
daytime clinical hypoglycemia on the electrocardiogram in young people with type 1 
diabetes.  
Research Design and Methods 
Thirty-seven individuals with type 1 diabetes underwent 96 hours of simultaneous 
ambulatory electrocardiogram (ECG) and blinded continuous interstitial glucose monitoring 
(CGM) while recording symptomatic hypoglycemia. Frequency of arrhythmias, heart rate 
variability and cardiac repolarization were measured during hypoglycemia and compared to 
time-matched euglycemia separately at night and day.  
Results 
A total of 2395 hours of simultaneous ECG and CGM recordings were obtained; 159 hours 
were designated hypoglycemia and 1355 hours euglycemia. Median (interquartile range) 
duration of nocturnal hypoglycemia 60 (40 ± 135) min was longer than daytime 
hypoglycemia 44 (30 ± 70) min (p = 0.020). Only 24.1% of nocturnal and 51.0% of daytime 
episodes were symptomatic. Bradycardia was more frequent during nocturnal hypoglycemia 
compared to matched euglycemia (Incident rate ratio (IRR) 6.44 [95% CI 6.26 ± 6.66], p < 
0.001). During daytime hypoglycemia, bradycardia was less frequent (IRR 0.023 [95% CI 
0.002 ± 0.26], p = 0.002) and atrial ectopics more frequent (IRR 2.29 [95% CI 1.19 ± 4.39], p 
= 0.013) compared to euglycemia. Prolonged rate-corrected QT (QTc), TpTend interval and 
decreased T-wave symmetry were detected during nocturnal and daytime hypoglycemia.  
Conclusions 
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We have identified differences in arrhythmic risk and cardiac repolarization during nocturnal 
versus daytime hypoglycemia in young adults with type 1 diabetes. Asymptomatic 
hypoglycemia was common and our data support the concept of hypoglycemia as 
a proarrhytmogenic state.   
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Hypoglycemia is an inevitable consequence of the current management of type 1 diabetes (1). 
Improved glycemic control is frequently accompanied by an increased risk of inducing 
iatrogenic hypoglycemia (2). Observational studies indicate that rates of severe hypoglycemia 
have generally not fallen despite the introduction of insulin analogues and advanced methods 
of glucose monitoring (3, 4). Hypoglycemia thus continues to be a major limiting factor in 
the management of type 1 diabetes.  
It has been nearly three decades since Tatersall and Gill published their original  report 
describing 22 nocturnal deaths of young people with type 1 diabetes (5). 7KH µGHDG LQEHG
V\QGURPH¶ ZDV FKDUDFWHUL]HG E\ \RXQJ DQG otherwise healthy individuals with type 1 
diabetes who had retired to bed in good health but were found dead in undisturbed beds on 
the following day. Subsequent autopsies could not establish a cause of death. Similar reports 
from other parts of the world have continued to appear in the literature (6-8). 
Nocturnal hypoglycemia has been consistently implicated, yet the precise mechanism 
remains unclear. A case report involving continuous interstitial glucose monitoring (CGM) 
has confirmed that hypoglycemia was present at the time of death (9). Our group and others 
have reported QT interval prolongation during both experimental hypoglycemia in healthy 
individuals (10) and people with diabetes (11) as well as during clinical episodes (12). 
Abnormal cardiac repolarization during hypoglycemia appears to be mediated by both direct 
effect of sympathoadrenal stimulation and catecholamine and insulin-induced hypokalemia 
on cardiac ion channels (13). Hypoglycemia is increasingly recognized as a potential 
proarrhythmic event (14), but direct evidence linking electrocardiographic changes and the 
µGHDGLQEHG¶V\QGURPHLVPLVVLQJ(15).  
Given the fact that nocturnal hypoglycemia is very common and sudden deaths in type 1 
diabetes are rare (6, 16) an  interplay of several factors such as overt or undetected autonomic 
neuropathy, genetic contribution or abnormally intensive sympathoadrenal response are likely 
to contribute (14). There is, however, considerable uncertainty in the way and extent in which 
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these factors contribute to the development of the presumed malignant disturbances of 
cardiac rhythm (6, 17, 18). Presumably only under certain circumstances a combination of 
these and perhaps other factors can lead to an unfavorable course of events resulting in a fatal 
outcome.  
2QHRI WKHGHILQLQJFKDUDFWHULVWLFVRI WKH µGHDG LQEHG¶ V\QGURPH LV that it seems to occur 
only at night. A physiological diurnal variability in the autonomic tone with  reduction in 
sympathetic tone and consequent  relative increase in parasympathetic activity during sleep 
has been well documented (19). Diminished epinephrine responses to experimental 
hypoglycemia during sleep in comparison to daytime hypoglycemia have been reported in 
people with type 1 diabetes and healthy individuals (20). Additionally, we have recently 
reported differences in increased susceptibility to cardiac arrhythmias, heart rate variability 
(HRV) and cardiac repolarization during nocturnal and daytime hypoglycemia in people with 
type 2 diabetes with increased cardiovascular risk in a study design similar to the currently 
presented report (21). We have hypothesized that similar diurnal differences in cardiac 
electrophysiological responses to hypoglycemia may exist in young people with type 1 
diabetes and if so, could help to elucidate WKHSDWKRSK\VLRORJ\RIWKHµGHDGLQEHG¶V\QGURPH. 
The aim of this study was to examine the HIIHFWRIFOLQLFDOK\SRJO\FHPLDLQ\RXQJSHRSOH
50 years of age) with type 1 diabetes ± as compared to matched euglycemia - on the 
frequency of cardiac arrhythmias, HRV and cardiac repolarization. We particularly sought to 
compare differences between nocturnal and daytime hypoglycemia given the above described 
diurnal differences in sympathetic adrenomedullary responses to hypoglycemia.  
RESEARCH DESIGN AND METHODS 
Thirty±seven individuals with type 1 diabetes below the age of 50 years and with duration of 
disease for at least 4 years were recruited from Sheffield Teaching Hospitals outpatient 
clinics. Participants taking beta-blocking and QT-interval prolonging agents were excluded. 
 6 
Baseline 12-lead electrocardiogram (ECG) was performed prior to further testing and 
participants with bundle branch block or atrial fibrillation were excluded. We also excluded 
participants with diabetic maculopathy and severe visual impairment as well as participants 
with estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73m2. Data on presence and 
severity of diabetic microvascular complications were obtained from local electronic patient 
database. Written informed consent was obtained from all participants and the study received 
local ethics approval. 
Baseline Assessment 
Urea, electrolytes and glycated haemoglobin A1c (HBA1c) were measured at the onset of the 
monitoring period. HBA1c was established using ion-exchange high-performance liquid 
chromatography. Cardiovascular autonomic tests were performed at the onset of the 
monitoring period in accordance with a recently published consensus statement (22). ECG 
signals were acquired using a g.USBamp biosignal amplifier unit together with the 
g.Recorder software (g.tec Medical Engineering GMBH, Schiedlberg, Austria) and analysis 
was undertaken using custom software written in MATLAB (MathWorks, Natick, 
Massachusetts, USA). Participants were instructed to avoid vigorous exercise, caffeine and 
smoking 12 hours prior to morning testing. Participants were classified as possible cardiac 
autonomic neuropathy (CAN) when one cardioreflex test was below the age-adjusted 
reference range and definite CAN when two or more cardioreflex tests were below the age-
adjusted reference range (22, 23). Hypoglycemia awareness was assessed using a visual 
analogue Likert-type scale of 1 to 7, as previously described (24).  
Monitoring 
All participants underwent 96 hours of simultaneous 12-lead Holter ECG and CGM 
monitoring. Participants carried on with their usual daily activities and diabetes management. 
Twelve-lead high-frequency ambulatory ECGs (Mortara H12+; Mortara Instrument Inc. 
 7 
Milwaukee, Wisconsin, USA) were recorded at a 1000 Hz sampling rate with electrodes in a 
Mason-Likar configuration. Participants also had a time-synchronized CGM monitoring 
system attached (FreeStyle Navigator II, Abbott Diabetes Care, Maidenhead, UK). 
Calibrations were performed at least five times during the study period according to the 
manufacturer`s instructions. Mindful of the potential limitations of the CGM, we selected a 
system that with the lowest detection limit of 1.1 mmol/L (20 mg/dL) and with acceptable 
mean absolute differences between the interstitial glucose (IG) values and actual blood 
glucose levels (25). Predictive alarms were switched off and participants were blinded to the 
real-time IG levels by disabling the display of IG values on the device. Participants were 
asked to keep a record of any symptomatic hypoglycemia in provided diaries. Any 
hypoglycemia episode, as defined in the next paragraph, without simultaneous self-report of 
symptoms in the diary was regarded as asymptomatic.   
CGM Analysis 
The IG was measured every minute by the CGM, and 10-min averages were reported 
(CoPilot Health Management; Abbott Diabetes Care). Hypoglycemia was defined as IG  3.5 
mmol/L in accordance with previously published studies (21, 26). Euglycemia was defined as 
an IG value between 5 and 10 mmol/L. We defined a valid hypoglycemic episode as a period 
of IG below the threshold for  20 min (27). The first reading of IG  3.5 mmol/L marked the 
start of the hypoglycemia, and the first reading of IG  3.5 mmol/L signified the end of the 
episode. The lowest IG within the hypoglycemic episode was designated the hypoglycemia 
nadir and was matched with a euglycemic time point from the same individual at the same 
time (within 20 min) on a different day.  
Arrhythmia Analysis 
The 12-lead Holter ECG data were reviewed using H-Scribe 4.34 software (Mortara 
Instrument Inc.). The software automatically separated normal ECG traces from artifacts and 
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detected arrhythmic events according to predetermined event definitions. These included 
atrial ectopic beats (prematurity threshold 30%), bradycardia (consecutive beats at rate <45 
bpm for >5 seconds), single ventricular premature beats (VPBs), complex VPBs (VPB 
couplets and runs) and total VPBs (sum of all VPBs). All identified arrhythmic events were 
manually verified for accuracy and modified if needed. Investigators were blinded to glucose 
values during arrhythmia identification. Hourly counts for each type of arrhythmia were 
provided by H-Scribe 4.34 software and were paired with hourly mean IG, which was 
categorized into hypoglycemia (mean hourly IG value PPRO/) and euglycemia (mean 
hourly IG value between 5 and 10 mmol/L). Analyses were separated into day and night 
(23.00 ± 07.00 h) to take into account diurnal variation. 
Heart Rate Variability Analysis 
R-R intervals were calculated from annotated normal beats (NN intervals), which were 
identified by the H-Scribe 4.34 software. A 5-min segment of successive NN intervals, 
centered on the nadir IG value was selected and spectral analysis was performed using 
Fourier transformation. Spectral analysis was performed in accordance with 
recommendations of the Taskforce on Heart Rate Variability (28). The low-frequency (LF) 
band was defined as 0.04 ±0.15 Hertz (Hz) and high-frequency (HF) band as 0.15 ± 0.4 Hz. 
The ratio between the LF power and total power (LF + HF power) was calculated (LFnorm). 
HF power reflects parasympathetic activity. LFnorm was previously suggested to indicate the 
level of sympathetic modulation in HRV (29, 30). 
Repolarization Analysis 
Repolarization analysis and detection of QT interval duration was performed using custom-
built, semiautomatic software based on a selective beat averaging approach (31). Cubic spline 
interpolation and 40Hz low-pass filtering were applied to ECG leads. Average beats were 
calculated from stable normal beats within 5-min segments, centered on each IG value.  
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Analysis was performed on a composite wave, which was calculated by combining averaged 
beats derived from leads I, II, and V5 (31). The onset of the Q wave was marked as the first 
positive deflection from the isoelectric line > 10 microvolts. The end of the T wave was 
determined using the tangent method, where the tangent to the steepest downslope of the T 
wave crosses the isoelectric line. All fiducial points were reviewed and adjusted if necessary 
by an observer blinded to glucose values. QT intervals were corrected for heart rate (QTc) 
using %D]HWW¶V IRUPXOD (32). Cardiac repolarization was characterized by calculating rate-
independent parameters, including T-peak to T-end interval duration (TpTend) and symmetry 
of the T wave (Tsym) (33). All parameters, including HRV indices were compared at 
hypoglycemia nadir vs matching euglycemia as described in the next paragraph. 
Statistical Analysis 
This was an observational study, and thus no power calculations were performed. The 
numbers chosen were based upon an assessment of the number of patients it was possible to 
examine given the constraints on recruitment and projected hypoglycemia rates. Data were 
inspected for normality. Data that followed an approximate normal distribution were 
summarized using mean ± SD, while skewed data were summarized using the median (IQR). 
Median duration and median nadir values of nocturnal and daytime hypoglycemic episodes 
were compared using the Mann-Whitney U test. The generalized estimated equations 
approach was used to investigate the effect of glycemic status on arrhythmia counts while 
taking into account correlated measurements from individuals who experienced more than 
one episode of hypoglycemia or hyperglycemia. Data were fitted with a negative binomial 
model with the assumption that rates for individuals came from a distribution with a mixed 
but non-zero variance.  This allows modelling of variables that are over-dispersed (i.e. where 
the sample variance exceeds the sample mean) relative to a Poisson model which is usually 
used in analyzing count data. A first-order autoregressive correlation structure was applied to 
adjust for within-individual correlation. Exponentiated regression coefficients represent 
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incident rate ratios (IRRs). The IRRs of arrhythmias during hypoglycemia compared with 
euglycemia were calculated adjusting for the longer period participants were at euglycemic 
levels compared to the period spent in hypoglycemia . HRV, corrected QT intervals (QTc) 
and repolarization parameters were compared at the hypoglycemia nadir against an 
equivalent euglycemic time point on a different day. Where there was more than one 
matching hypoglycemic-euglycemic episode in an individual participant over the course of 
the recording period, the mean values from all daytime and nocturnal episodes from that 
individual were reported. Data were compared using a paired t-test or the Mann-Whitney U 
test. Statistical analysis was performed with SPSS (version 22; IBM, Chicago, Illinois, USA). 
A p value  0.05 was deemed statistically significant. 
 
RESULTS 
Participant Characteristics 
A total of 3165 hours of interstitial glucose (IG) recordings and 2395 hours of valid 
simultaneous ECG and IG recordings were obtained from 37 participants. 159 hours of IG 
data were recorded in the hypoglycemic range out of which 88 hours were recorded during 
the night and 71 hours during the day. Out of 1355 hours of  euglycemia, 506 hours were 
recorded during the night and 849 hours during daytime (Supplementary Figure 1). Baseline 
participant characteristics are shown in Table 1. Of 37 participants, 32 (86.5%) experienced 
at least one episode of hypoglycemia; 23 (62.2%) experienced at least one episode of 
nocturnal hypoglycemia and 28 (75.7%) experienced at least one episode of daytime 
hypoglycemia.  
Nocturnal and Daytime Hypoglycemia Characteristics 
Altogether 44 nocturnal and 69 daytime hypoglycemic episodes were analyzed. There were 
diurnal differences in the duration of hypoglycemic episodes (Table 2). The median (IQR) 
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duration of nocturnal hypoglycemic episodes was 60 (40 ± 135) min significantly longer than 
the duration of daytime hypoglycemic episodes 44 (30 ± 70) min (p = 0.020). There was 
a trend towards lower glucose at nadir of nocturnal hypoglycemia, median (IQR) 2.66 (1.89 ± 
3.14) mmol/L in comparison to nadir of daytime hypoglycemia 3.00 (2.44 ± 3.22) mmol/L, 
but the difference did not reach statistical significance (p = 0.116). 
Symptomatic versus Asymptomatic Hypoglycemia Episodes 
Participants were provided with diaries to keep record of any symptomatic hypoglycemia for 
the duration of the monitoring period. The return rate of the diaries was 26/37 (70.3%). Out 
of 29 nocturnal hypoglycemia episodes detected by CGM in these participants, only 7 were 
reported symptomatic (24.1%), and out of 49 daytime hypoglycemia episodes 25 were 
reported symptomatic (51.0%). We did not detect any significant differences in relation to 
duration or nadir values between symptomatic and asymptomatic hypoglycemia episodes. 
The median (IQR) duration of nocturnal symptomatic hypoglycemic episodes was 60 (50 ± 
90) min with a nadir glucose 2.77 (2.55 ± 3.27) mmol/L. The median (IQR) duration of 
nocturnal asymptomatic hypoglycemic episodes was 45 (20 ± 113) min with a nadir value 
2.77 (1.79 ± 3.20) mmol/L. During the day, the median (IQR) duration of symptomatic 
hypoglycemic episodes was 50 (30 ± 70) min and of asymptomatic episodes 40 (23 ± 70) 
min. Combining daytime and nightime hypoglycemic episodes, there was a trend towards 
lower nadir values during symptomatic 2.83 (2.28 ± 3.13) mmol/L versus asymptomatic 
episodes 3.13 (2.62 ± 3.33) mmol/L (p = 0.055).  
Arrhythmias during Nocturnal and Daytime Hypoglycemia 
We compared total and relative frequencies of distinct types of arrhythmias during 
hypoglycemia versus euglycemia during night and day. Total frequencies of arrhythmias 
were low (Supplementary Table 1). However, comparison of relative frequencies showed 
several differences between hypoglycemia and euglycemia and between nocturnal and 
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daytime hypoglycemia, respectively (Figure 1). Bradycardia was more than six-fold higher 
during nocturnal hypoglycemia compared with nocturnal euglycemia (Incident rate ratio IRR 
6.44 [95% CI 6.26 ± 6.66], p < 0.001). On the contrary, bradycardia was significantly less 
frequent during daytime hypoglycemia compared with daytime euglycemia (IRR 0.023 [95% 
CI 0.002 ± 0.26], p = 0.002). The median duration (min-max) of nocturnal bradycardic 
episodes was 5 (5-23) seconds. The median duration (min-max) of daytime bradycardic 
episodes was 5 (5-786) seconds. During daytime hypoglycemia frequency of atrial ectopics 
was more than two-fold higher in comparison to euglycemia (IRR 2.29 [95% CI 1.19 ± 4.39], 
p = 0.013). We did not detect any significant differences in frequencies of ventricular 
arrhythmias during nocturnal or daytime hypoglycemia in comparison to euglycemia (Figure 
1). 
Heart Rate Variability  
In relation to HRV and cardiac repolarization characteristics we analyzed 45 nocturnal 
hypoglycemic episodes in 21 participants and 59 daytime hypoglycemic episodes in 24 
participants and compared them with time-matched euglycemia. Episodes to which at least 
one time-matched euglycemic episode could not be found were not included. 
HRV parameters at nadir of nocturnal and daytime hypoglycemia were compared with 
matched euglycemic episodes. Cardio-acceleration was detected during daytime 
hypoglycemia (mean heart rate (HR) 80 ± 14 bpm) compared with matched euglycemia 
(mean HR 77 ± 12 bpm); mean paired difference (95%CI) 3.5 (0.5 ± 6.4), p = 0.022, which 
was accompanied by a trend towards lower HF power (p = 0.106) and RMSSD (p = 0.078). 
Low frequency power (logLF) was significantly lower during daytime hypoglycemia (2.82 ± 
0.31) in comparison to euglycemia (2.90 ± 0.27); mean paired difference (95%CI) -0.077 (-
0.151 ± [-0.004]), p = 0.04. No differences in heart rate and parameters of HRV were 
detected during nocturnal hypoglycemia compared with matched euglycemia (Table 3).  
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Cardiac Repolarization  
Mean QTc was prolonged during nocturnal hypoglycemia (405 ± 27 ms) compared with 
euglycemia (400 ± 22 ms); mean paired difference (95% CI) 5.4 (0.5 ± 10.3) ms, p = 0.031 as 
well as during daytime hypoglycemia (413 ± 30 ms) compared with euglycemia (401 ± 29 
ms); mean paired difference (95% CI) 11.7 (5.7 ± 17.6) ms, p < 0.001 (Table 3). TpTend was 
prolonged during nocturnal hypoglycemia (71 ± 9 ms) compared with matched euglycemia 
(67 ± 7 ms); mean paired difference (95% CI) 4.95 (2.76 ± 7.14) ms, p <  0.001, with 
corresponding decrease in T wave symmetry: Tsym (1.64 ± 0.41 vs. 1.77 ± 0.27); mean 
paired difference (95% CI) -0.13 (-2.23 ± [-0.04]), p = 0.007. TpTend was also prolonged 
during daytime hypoglycemia (74 ± 12 ms) compared with matched euglycemia (69 ± 12 
ms), mean paired difference (95% CI) 5.41 (2.53 ± 8.30), p < 0.001, with corresponding 
decrease in Tsym (1.42 ± 0.35 vs. 1.54 ± 0.34), mean paired difference (95% CI) -0.12 (-0.20 
± [-0.04]), p = 0.002) (Table 3). 
We examined changes in HRV and cardiac repolarization parameters during a 440 min long 
asymptomatic nocturnal hypoglycemic episode in a 29-year old male participant with CAN 
(Supplementary Figure 2, panels A-G). This was the only nocturnal hypoglycemic episode 
recorded in a participant with CAN and also one of the longest of all episodes. Interestingly, 
cardiac repolarization parameters during this episode show opposite trends than the mean 
values across all episodes as described in the previous paragraph. QTc and TpTend tend to 
decrease over the duration of the hypoglycemia (panels E and F), along with gradually 
increasing Tsym (panel G). Only 1 nocturnal and 2 daytime hypoglycemia episodes in 3 
participants with confirmed CAN were identified, which precludes any further statistical 
analysis of the above parameters. 
CONCLUSIONS 
To the best of our knowledge this is the largest observational study to date examining the 
effect of spontaneous hypoglycemia in young people with type 1 diabetes on frequency of 
 14 
cardiac arrhythmias, heart rate variability (HRV) and cardiac repolarization and the first 
study that directly compares diurnal differences in these characteristics. We confirmed that 
hypoglycemia and particularly asymptomatic hypoglycemia continues to occur frequently in 
young people with type 1 diabetes. We also observed several differences in cardiac 
electrophysiological responses to hypoglycemia between day and night. We saw increased 
risk of bradycardia during nocturnal hypoglycemia whereas during daytime hypoglycemia, 
bradycardia was significantly lower and frequency of atrial ectopics significantly higher in 
comparison to euglycemia. Cardio-acceleration was detected during daytime hypoglycemia 
but not during nocturnal hypoglycemia. Lastly, we confirmed a pro-arrhythmogenic effect of 
hypoglycemia by showing significant prolongation of QTc interval and TpTend interval 
together with a change towards abnormal, symmetric shape of the T wave both during night 
and day.   
One of the main objectives of this study was to explore the different effects of nocturnal and 
daytime hypoglycemia on frequency of cardiac arrhythmias, HRV and cardiac repolarization. 
Factors which might affect these responses include diurnal variability in autonomic tone (19), 
different sympathoadrenal response to hypoglycemia when awake or asleep (20) and the 
effect of body position (34). Previous studies in this field have either compared 
measurements of cardiac repolarization during hypoglycemia to those at euglycemia 
immediately before hypoglycemia (26) or averaged HRV and repolarization across the total 
duration of episodes (35). We chose to compare measurements at glucose nadir. In this way 
we hoped to avoid a bias due to a variable length of episodes (the range of the duration 
ranged from 20 to 460 minutes) as well as averaging out the changes during phasic responses 
in episodes of long duration. We also controlled robustly for diurnal increases in arrhythmic 
risk by comparing changes during a matched period of euglycemia at the same time on a 
different day.  
 15 
However pre-defining a hypoglycaemic episode precisely imposes its own limitation.  By 
only counting hypoglycemic episodes that lasted at least 20 min, we probably underestimated 
the amount of hypoglycaemia. Nevertheless since we defined euglycemia as a glucose 
concentration between 5-10 mmol/l, we are confident that periods defined as euglycemia (to 
control for circadian influences on arrhythmias) were calculated accurately. A further 
limitation was the 70% return rate of questionnaires used to identify symptomatic responses.   
While this probably represents a reasonably good return in an observational clinical study our 
estimates of symptomatic and asymptomatic hypoglycaemia must be regarded with some 
uncertainty.  
Absolute numbers of arrhythmias in the studied population were low meaning that we were 
unable to measure the changes in sub-groups, such as those with CAN. The majority of 
cardiac arrhythmias occurred during euglycemia, since periods of euglycemia were more 
frequent and long-lasting compared to hypoglycemia. Relative risks for distinct types of 
arrhythmias during hypoglycemia versus euglycemia are reflected by presented incident rate 
ratios (IRRs). The applied statistical model was used to adjust for uneven distribution of 
hypoglycemic episodes and cardiac arrhythmias among studied individuals as well as to 
adjust for individuals with no episodes and those who experienced multiple episodes of 
hypoglycemia. However, arrhythmia incident rate ratios are weighted by data from 
individuals who are more prone to arrhythmias and the findings need to be confirmed by 
studies in different populations. 
The QT interval duration varies according to heart rate and different formulas are used to 
correct for heart rate, of which Bazett`s correction is the most commonly used.  The Bazett`s 
formula corrects intervals to a rate of 60 bpm and tends to result in overcorrection at high 
heart rates and under-correction at lower heart rates.  Nevertheless, it is generally considered 
a reasonably accurate correction in the setting of hypoglycemia (36).  In our study we 
detected a mean QTc prolongation of 5 ms during nocturnal hypoglycemia and 12 ms during 
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daytime hypoglycemia in comparison to matched euglycemia. Despite being smaller than the 
differences in QTc duration measured during experimental hypoglycemia (attributed to lower 
insulin levels and sympathoadrenal responses during spontaneous compared to experimental 
episodes) (12, 18), the comparison with mean QTc duration during matched euglycemia 
reached statistical significance (p < 0.001). QTc prolongation of this scale are probably 
clinically relevant, given that the current FDA recommendations for testing the effects of new 
agents on QT/QTc interval prolongation  indicate a difference in QT/QTc of 5 ms or larger as 
a reason for regulatory concern (37).  
In the light of the potential limitations of heart rate correction, we also included 
measurements of rate-independent indicators of cardiac repolarization: T-peak to T-end 
interval duration (TpTend) and symmetry of the T wave (Tsym) (33). TpTend is a measure of 
dispersion of repolarization in the left ventricle; its prolongation is considered to represent a 
period of potential vulnerability to re-entrant ventricular dysrhythmias and is associated with 
increased risk of sudden cardiac death (38). We detected significant prolongation of TpTend 
in both nocturnal and daytime hypoglycemia. Symmetrical T waves can be found in various 
pathological states and computational models show that T waves become more symmetrical 
with an increase in the dispersion of repolarization (39). In our study T waves did not become 
totally symmetric (Tsym = 1) but we found a consistent change towards more symmetrical 
shape during hypoglycemia both during day and night. 
Cardio-acceleration and a trend towards vagal withdrawal were observed during daytime 
hypoglycemia together with greater increase in QTc.  In contrast, during nocturnal 
hypoglycemia no changes in HRV were detected and QTc increases were smaller. We 
reported similar findings in an ambulatory study in type 2 diabetes (21). One potential 
mechanism is a predominance of sympathoadrenal response during the day compared to the 
night where sympathoadrenal activation may be suppressed by prone posture and during 
sleep (21).  
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In contrast to differences in the magnitude of QTc prolongation, the observed changes in rate-
independent characteristics of cardiac repolarization (TpTend, Tsym) during daytime and 
nighttime hypoglycemia are rather similar. This suggests that during hypoglycemia, cardiac 
repolarization is influenced by factors additional to cardiac autonomic responses, perhaps 
hypokalemia or hypoglycemia per se. In this observational study no direct measurements of 
catecholamine or potassium levels were possible.  
Increased frequency of bradycardias during nocturnal hypoglycemia in young people with 
type 1 diabetes might be clinically relevant given the fact that bradycardia may lead to early 
afterdepolarizations (EADs) via increased intracellular Ca2+ concentration in cardiomyocytes 
(40). EADs represent one of the most important arrhythmogenic mechanisms promoting 
arrhythmias in acquired and congenital long QT syndromes including torsade des pointes, 
polymorphic ventricular tachycardia and ventricular fibrillation (40). Additionally, diabetes 
and hypoglycemia per se are linked with increased incidence of EADs independent of heart 
rate (14). Nocturnal hypoglycemia with concomitant bradycardia in people with diabetes thus 
represents an event with increased proarrhythmogenic potential. We have previously reported 
an increased risk of bradycardias during spontaneous nocturnal hypoglycemia in people with 
type 2 diabetes at increased cardiovascular risk (21). The findings in the present study 
suggest that this hypoglycemia-induced mechanism is independent of the type of diabetes, 
age or cardiovascular risk profile. Importantly, our observations that certain types of 
arrhythmia (for example, bradycardia) were confined to just a few subjects suggest that 
susceptibility to arrhythmias during hypoglycaemia is highly individual. The increasing use 
of CGM as a clinical rather than a research tool might permit screening of individuals with 
type 1 diabetes to identify those at high arrhythmic risk. 
In summary, we have shown a contrast in the frequencies of arrhythmias and cardiac 
electrophysiological responses during nocturnal compared to daytime hypoglycemia. We 
confirm a high frequency of hypoglycemia, particularly of nocturnal asymptomatic episodes 
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among young people with type 1 diabetes and our data add to the body of evidence 
suggesting that hypoglycemia is pro-arrhythmogenic.  
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Tables 
Table 1 ± Baseline participant characteristics  
Number of participants , n 37 
Age (years)  34 (25.5 ± 40.5) 
Male, n (%)  19 (51.4%) 
Duration of diabetes (years) 19.3 ± 9.6 
Insulin regimen  
  Basal ± prandial (MDI), n (%) 26 (70.3%) 
  Twice daily biphasic, n (%) 4 (10.8%) 
  Insulin pump (CSII), n (%) 7 (18.9%) 
Insulin type  
  Human, n (%)  4 (10.8%) 
  Analog, n (%)  31 (83.8%) 
  Human and analog combined, n (%) 2 (5.4%) 
HbA1C  
  % 8.1 (7.5 ± 8.8) 
  mmol/mol  65 (58.5 ± 73) 
BMI (kg/m2) 25 (22.8 ± 27.9) 
SBP (mmHg) 123 ± 13 
DBP (mmHg) 72 ± 7  
Heart rate (bpm) 73 ± 14 
Baseline  QTc (ms) 417 ± 27 
Baseline creatinine (umol/L) 72.5 (55.5 - 89.5) 
Baseline potassium (mmol/L) 4.55 (4.05 - 4.95) 
GOLD score (1-7) (n=26)  
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Data are displayed as mean ± SD or median (interquartile range). MDI ± multiple daily 
injections of insulin. CSII ± continuous subcutaneous insulin infusion. SBP ± systolic blood 
  1 7/26 (26.9%) 
  2-3 16/26 (61.5%) 
   3/26 (11.5%) 
CAN status  
  possible CAN, n (%) 5 (13.5%) 
  definitive CAN, n (%) 3 (8.1%) 
  no CAN, n (%) 29 (78.4%) 
Diabetic retinopathy  
  R0 9/37 (24.3%) 
  R1 19/37 (51.4%) 
  R2 4/37 (10.8%) 
  R3 5/37 (13.5%) 
Diabetic peripheral neuropathy   
  No DSPN 36/37 (97.3%) 
  Possible DSPN 1/37 (2.7%) 
Diabetic nephropathy  
  Absent  32/37 (86.5%) 
  Microalbuminuria* 5/37 (13.5%) 
  Macroalbuminuria  0/37 (0%) 
eGFR  
  >90 ml/min/1.73m2 (CKD1) 24/37 (64.9%) 
  60-89 ml/min/1.73m2 (CKD2) 12/37 (32.4%) 
  30-59 ml/min/1.73m2 (CKD3) 1/37 (2.7%) 
 24 
pressure, DBP ± diastolic blood pressure. CAN ± cardiac autonomic neuropathy. DSPN ± 
chronic sensorimotor distal symmetrical polyneuropathy. *Microalbuminuria was defined as 
albumin/crHDWLQLQH UDWLRmg/mmol PHQDQG mg/mmol (women) on 2 separate 
measurements at least 6 months apart. Macroalbuminuria was defined as albumin/creatinine 
ratio > 30 mg/mmol. eGFR ± estimated glomerular filtration rate (CKD-EPI formula). 
CKD1-3 ± chronic kidney disease stages 1-3. 
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Table 2 -  Comparison of nocturnal and daytime hypoglycemic episodes 
 NIGHTTIME DAYTIME p 
Episodes, n 44 69  
Participants who experienced at 
least one episode, n/total (%) 
23/37 (62.2%) 28/37 (75.7%)  
Symptomatic episodes, n/total (%)  7/29 (24.1%) 25/49 (51.0%)  
Duration of episodes, median 
(IQR) (min) 
60 (40 ± 135) 44 (30 ± 70) 0.020 
Nadir, median (IQR) (mmol/L) 2.66 (1.89 ± 3.14) 3.00 (2.44 ± 3.22) 0.116 
 
P values indicate comparison of nocturnal and daytime hypoglycemic episode characteristics 
via Mann-Whitney U test. 
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Table 3 ± Heart rate variability and cardiac repolarization characteristics 
 
NIGHTTIME (n=45 episodes) 
Hypo Eu Mean diff. 95% CI p 
Heart rate (bpm) 68 ± 12 66 ± 9 1.5 (-1.3, 4.4) 0.285 
SD NN (ms) 68.1 ± 42.7 67.8 ± 34.7 0.28 (-12.30, 12.85) 0.965 
RMSSD (ms) 33.0 ± 15.1 32.8 ± 14.1 0.21 (-2.70, 3.13) 0.884 
log LF 2.74 ± 0.49 2.75 ± 0.44 -0.009 (-0.115, 0.097) 0.871 
log HF 2.26 ± 0.48 2.25 ± 0.49 0.006 (-0.082, 0.094) 0.89 
LF normalised 0.73 ± 0.14 0.74 ± 0.13 -0.004 (-0.041, 0.033) 0.829 
QTc (ms) 405 ± 27 400 ± 22 5.4 (0.5, 10.3) 0.031 
TpTend (ms) 71.5 ± 9.4 66.5 ± 7.3 4.95 (2.76, 7.14) <0.001 
TpTend_cB (ms) 75.7 ± 11.9 69.6 ± 7.7 6.06 (3.33, 8.78) <0.001 
Tsym 1.64 ± 0.41 1.77 ± 0.27 -0.132 (-0.226, -0.037) 0.007 
 DAYTIME (n=59 episodes)   
 Hypo Eu Mean diff. 95% CI p 
Heart rate (bpm) 80 ± 14 77 ± 12 3.5 (0.5, 6.4) 0.022 
SD NN (ms) 61.1 ± 28.9 61.5 ± 20.8 -0.35 (-7.67, 6.96) 0.923 
RMSSD (ms) 27.5 ± 12.8 29.6 ± 12.7 -2.16 (-4.57, 0.25) 0.078 
log LF 2.82 ± 0.31 2.90 ± 0.27 -0.077 (-0.151, -0.004) 0.040 
log HF 2.18 ± 0.46 2.25 ± 0.42 -0.075 (-0.166, 0.016) 0.106 
LF normalised 0.79 ± 0.12 0.80 ± 0.08 -0.009 (-0.034, 0.017) 0.506 
QTc (ms) 413 ± 30 401 ± 29 11.7 (5.7, 17.6) <0.001 
TpTend (ms) 74.2 ± 12.3 68.8 ± 12.3 5.41 (2.53, 8.30) <0.001 
TpTend_cB (ms) 84.2 ± 14.9 76.6 ± 15.8 7.61 (3.61, 11.62) <0.001 
Tsym 1.42 ± 0.35 1.54 ± 0.34 -0.121 (-0.197, -0.045) 0.002 
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Data are displayed as mean ± SD. RMSSD ± root mean square of successive differences 
between adjacent NN intervals. TpTend ± T-peak to T-end interval duration. TpTend_cB - 
TpTend interval corrected for heart rate (Bazett`s formula). Mean diff. ± mean paired 
difference. P values indicate comparison of nocturnal and daytime hypoglycemic data via 
paired t-test. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 28 
 
Figure 1 ± Incident rate ratios (IRRs) of distinct types of arrhythmias during hypoglycemia 
vs. euglycemia. Comparison between nocturnal (23.00 ± 07.00h) and daytime episodes. No 
complex ventricular paroxysmal beats (VPBs) were detected during nocturnal hypoglycemia 
(see also Table 3) and therefore no IRR could be calculated for this type of arrhythmia. P ± 
significance of difference in arrhythmia rates during hypoglycemia vs. euglycemia. 
 
 
